Global Targeting p53 Cancer Therapies Market Growth 2026-2032
The global Targeting p53 Cancer Therapies market size is predicted to grow from US$ million in 2025 to US$ million in 2032; it is expected to grow at a CAGR of %from 2026 to 2032.
The essence of p53-targeted therapy is to regain the 'tumor suppressor function' of the mutated p53 protein, or indirectly protect the 'tumor suppressor function' of p53 by inhibiting other targets that can inhibit the wild-type p53 protein.
United States market for Targeting p53 Cancer Therapies is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for Targeting p53 Cancer Therapies is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for Targeting p53 Cancer Therapies is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key Targeting p53 Cancer Therapies players cover Sibiono GeneTech, Kartos Therapeutics, SynerGene Therapeutics, MultiVir, Rain Oncology, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LP Information, Inc. (LPI) ' newest research report, the ?Targeting p53 Cancer Therapies Industry Forecast? looks at past sales and reviews total world Targeting p53 Cancer Therapies sales in 2025, providing a comprehensive analysis by region and market sector of projected Targeting p53 Cancer Therapies sales for 2026 through 2032. With Targeting p53 Cancer Therapies sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Targeting p53 Cancer Therapies industry.
This Insight Report provides a comprehensive analysis of the global Targeting p53 Cancer Therapies landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Targeting p53 Cancer Therapies portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Targeting p53 Cancer Therapies market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Targeting p53 Cancer Therapies and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Targeting p53 Cancer Therapies.
This report presents a comprehensive overview, market shares, and growth opportunities of Targeting p53 Cancer Therapies market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
The essence of p53-targeted therapy is to regain the 'tumor suppressor function' of the mutated p53 protein, or indirectly protect the 'tumor suppressor function' of p53 by inhibiting other targets that can inhibit the wild-type p53 protein.
United States market for Targeting p53 Cancer Therapies is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for Targeting p53 Cancer Therapies is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for Targeting p53 Cancer Therapies is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key Targeting p53 Cancer Therapies players cover Sibiono GeneTech, Kartos Therapeutics, SynerGene Therapeutics, MultiVir, Rain Oncology, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LP Information, Inc. (LPI) ' newest research report, the ?Targeting p53 Cancer Therapies Industry Forecast? looks at past sales and reviews total world Targeting p53 Cancer Therapies sales in 2025, providing a comprehensive analysis by region and market sector of projected Targeting p53 Cancer Therapies sales for 2026 through 2032. With Targeting p53 Cancer Therapies sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Targeting p53 Cancer Therapies industry.
This Insight Report provides a comprehensive analysis of the global Targeting p53 Cancer Therapies landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Targeting p53 Cancer Therapies portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Targeting p53 Cancer Therapies market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Targeting p53 Cancer Therapies and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Targeting p53 Cancer Therapies.
This report presents a comprehensive overview, market shares, and growth opportunities of Targeting p53 Cancer Therapies market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Small Molecule Drugs
- Immunotherapy
- Gene Therapy
- Others
- Hospital
- Clinic
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Sibiono GeneTech
- Kartos Therapeutics
- SynerGene Therapeutics
- MultiVir
- Rain Oncology
- Alieron Therapeutics
- Aprea Therapeutics
- Ascentage Pharma
- Jc (Wuxi) Company
- What is the 10-year outlook for the global Targeting p53 Cancer Therapies market?
- What factors are driving Targeting p53 Cancer Therapies market growth, globally and by region?
- Which technologies are poised for the fastest growth by market and region?
- How do Targeting p53 Cancer Therapies market opportunities vary by end market size?
- How does Targeting p53 Cancer Therapies break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Targeting p53 Cancer Therapies Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Targeting p53 Cancer Therapies by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Targeting p53 Cancer Therapies by Country/Region, 2021, 2025 & 2032
2.2 Targeting p53 Cancer Therapies Segment by Type
2.2.1 Small Molecule Drugs
2.2.2 Immunotherapy
2.2.3 Gene Therapy
2.2.4 Others
2.2.5 Targeting p53 Cancer Therapies Sales by Type
2.2.5.1 Global Targeting p53 Cancer Therapies Sales Market Share by Type (2021-2026)
2.2.5.2 Global Targeting p53 Cancer Therapies Revenue and Market Share by Type (2021-2026)
2.2.5.3 Global Targeting p53 Cancer Therapies Sale Price by Type (2021-2026)
2.3 Targeting p53 Cancer Therapies Segment by Application
2.3.1 Hospital
2.3.2 Clinic
2.3.3 Others
2.3.4 Targeting p53 Cancer Therapies Sales by Application
2.3.4.1 Global Targeting p53 Cancer Therapies Sale Market Share by Application (2021-2026)
2.3.4.2 Global Targeting p53 Cancer Therapies Revenue and Market Share by Application (2021-2026)
2.3.4.3 Global Targeting p53 Cancer Therapies Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Targeting p53 Cancer Therapies Breakdown Data by Company
3.1.1 Global Targeting p53 Cancer Therapies Annual Sales by Company (2021-2026)
3.1.2 Global Targeting p53 Cancer Therapies Sales Market Share by Company (2021-2026)
3.2 Global Targeting p53 Cancer Therapies Annual Revenue by Company (2021-2026)
3.2.1 Global Targeting p53 Cancer Therapies Revenue by Company (2021-2026)
3.2.2 Global Targeting p53 Cancer Therapies Revenue Market Share by Company (2021-2026)
3.3 Global Targeting p53 Cancer Therapies Sale Price by Company
3.4 Key Manufacturers Targeting p53 Cancer Therapies Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Targeting p53 Cancer Therapies Product Location Distribution
3.4.2 Players Targeting p53 Cancer Therapies Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR TARGETING P53 CANCER THERAPIES BY GEOGRAPHIC REGION
4.1 World Historic Targeting p53 Cancer Therapies Market Size by Geographic Region (2021-2026)
4.1.1 Global Targeting p53 Cancer Therapies Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Targeting p53 Cancer Therapies Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Targeting p53 Cancer Therapies Market Size by Country/Region (2021-2026)
4.2.1 Global Targeting p53 Cancer Therapies Annual Sales by Country/Region (2021-2026)
4.2.2 Global Targeting p53 Cancer Therapies Annual Revenue by Country/Region (2021-2026)
4.3 Americas Targeting p53 Cancer Therapies Sales Growth
4.4 APAC Targeting p53 Cancer Therapies Sales Growth
4.5 Europe Targeting p53 Cancer Therapies Sales Growth
4.6 Middle East & Africa Targeting p53 Cancer Therapies Sales Growth
5 AMERICAS
5.1 Americas Targeting p53 Cancer Therapies Sales by Country
5.1.1 Americas Targeting p53 Cancer Therapies Sales by Country (2021-2026)
5.1.2 Americas Targeting p53 Cancer Therapies Revenue by Country (2021-2026)
5.2 Americas Targeting p53 Cancer Therapies Sales by Type (2021-2026)
5.3 Americas Targeting p53 Cancer Therapies Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Targeting p53 Cancer Therapies Sales by Region
6.1.1 APAC Targeting p53 Cancer Therapies Sales by Region (2021-2026)
6.1.2 APAC Targeting p53 Cancer Therapies Revenue by Region (2021-2026)
6.2 APAC Targeting p53 Cancer Therapies Sales by Type (2021-2026)
6.3 APAC Targeting p53 Cancer Therapies Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Targeting p53 Cancer Therapies by Country
7.1.1 Europe Targeting p53 Cancer Therapies Sales by Country (2021-2026)
7.1.2 Europe Targeting p53 Cancer Therapies Revenue by Country (2021-2026)
7.2 Europe Targeting p53 Cancer Therapies Sales by Type (2021-2026)
7.3 Europe Targeting p53 Cancer Therapies Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Targeting p53 Cancer Therapies by Country
8.1.1 Middle East & Africa Targeting p53 Cancer Therapies Sales by Country (2021-2026)
8.1.2 Middle East & Africa Targeting p53 Cancer Therapies Revenue by Country (2021-2026)
8.2 Middle East & Africa Targeting p53 Cancer Therapies Sales by Type (2021-2026)
8.3 Middle East & Africa Targeting p53 Cancer Therapies Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Targeting p53 Cancer Therapies
10.3 Manufacturing Process Analysis of Targeting p53 Cancer Therapies
10.4 Industry Chain Structure of Targeting p53 Cancer Therapies
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Targeting p53 Cancer Therapies Distributors
11.3 Targeting p53 Cancer Therapies Customer
12 WORLD FORECAST REVIEW FOR TARGETING P53 CANCER THERAPIES BY GEOGRAPHIC REGION
12.1 Global Targeting p53 Cancer Therapies Market Size Forecast by Region
12.1.1 Global Targeting p53 Cancer Therapies Forecast by Region (2027-2032)
12.1.2 Global Targeting p53 Cancer Therapies Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Targeting p53 Cancer Therapies Forecast by Type (2027-2032)
12.7 Global Targeting p53 Cancer Therapies Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Sibiono GeneTech
13.1.1 Sibiono GeneTech Company Information
13.1.2 Sibiono GeneTech Targeting p53 Cancer Therapies Product Portfolios and Specifications
13.1.3 Sibiono GeneTech Targeting p53 Cancer Therapies Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Sibiono GeneTech Main Business Overview
13.1.5 Sibiono GeneTech Latest Developments
13.2 Kartos Therapeutics
13.2.1 Kartos Therapeutics Company Information
13.2.2 Kartos Therapeutics Targeting p53 Cancer Therapies Product Portfolios and Specifications
13.2.3 Kartos Therapeutics Targeting p53 Cancer Therapies Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Kartos Therapeutics Main Business Overview
13.2.5 Kartos Therapeutics Latest Developments
13.3 SynerGene Therapeutics
13.3.1 SynerGene Therapeutics Company Information
13.3.2 SynerGene Therapeutics Targeting p53 Cancer Therapies Product Portfolios and Specifications
13.3.3 SynerGene Therapeutics Targeting p53 Cancer Therapies Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 SynerGene Therapeutics Main Business Overview
13.3.5 SynerGene Therapeutics Latest Developments
13.4 MultiVir
13.4.1 MultiVir Company Information
13.4.2 MultiVir Targeting p53 Cancer Therapies Product Portfolios and Specifications
13.4.3 MultiVir Targeting p53 Cancer Therapies Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 MultiVir Main Business Overview
13.4.5 MultiVir Latest Developments
13.5 Rain Oncology
13.5.1 Rain Oncology Company Information
13.5.2 Rain Oncology Targeting p53 Cancer Therapies Product Portfolios and Specifications
13.5.3 Rain Oncology Targeting p53 Cancer Therapies Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Rain Oncology Main Business Overview
13.5.5 Rain Oncology Latest Developments
13.6 Alieron Therapeutics
13.6.1 Alieron Therapeutics Company Information
13.6.2 Alieron Therapeutics Targeting p53 Cancer Therapies Product Portfolios and Specifications
13.6.3 Alieron Therapeutics Targeting p53 Cancer Therapies Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Alieron Therapeutics Main Business Overview
13.6.5 Alieron Therapeutics Latest Developments
13.7 Aprea Therapeutics
13.7.1 Aprea Therapeutics Company Information
13.7.2 Aprea Therapeutics Targeting p53 Cancer Therapies Product Portfolios and Specifications
13.7.3 Aprea Therapeutics Targeting p53 Cancer Therapies Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Aprea Therapeutics Main Business Overview
13.7.5 Aprea Therapeutics Latest Developments
13.8 Ascentage Pharma
13.8.1 Ascentage Pharma Company Information
13.8.2 Ascentage Pharma Targeting p53 Cancer Therapies Product Portfolios and Specifications
13.8.3 Ascentage Pharma Targeting p53 Cancer Therapies Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Ascentage Pharma Main Business Overview
13.8.5 Ascentage Pharma Latest Developments
13.9 Jc (Wuxi) Company
13.9.1 Jc (Wuxi) Company Company Information
13.9.2 Jc (Wuxi) Company Targeting p53 Cancer Therapies Product Portfolios and Specifications
13.9.3 Jc (Wuxi) Company Targeting p53 Cancer Therapies Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Jc (Wuxi) Company Main Business Overview
13.9.5 Jc (Wuxi) Company Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Targeting p53 Cancer Therapies Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Targeting p53 Cancer Therapies by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Targeting p53 Cancer Therapies by Country/Region, 2021, 2025 & 2032
2.2 Targeting p53 Cancer Therapies Segment by Type
2.2.1 Small Molecule Drugs
2.2.2 Immunotherapy
2.2.3 Gene Therapy
2.2.4 Others
2.2.5 Targeting p53 Cancer Therapies Sales by Type
2.2.5.1 Global Targeting p53 Cancer Therapies Sales Market Share by Type (2021-2026)
2.2.5.2 Global Targeting p53 Cancer Therapies Revenue and Market Share by Type (2021-2026)
2.2.5.3 Global Targeting p53 Cancer Therapies Sale Price by Type (2021-2026)
2.3 Targeting p53 Cancer Therapies Segment by Application
2.3.1 Hospital
2.3.2 Clinic
2.3.3 Others
2.3.4 Targeting p53 Cancer Therapies Sales by Application
2.3.4.1 Global Targeting p53 Cancer Therapies Sale Market Share by Application (2021-2026)
2.3.4.2 Global Targeting p53 Cancer Therapies Revenue and Market Share by Application (2021-2026)
2.3.4.3 Global Targeting p53 Cancer Therapies Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Targeting p53 Cancer Therapies Breakdown Data by Company
3.1.1 Global Targeting p53 Cancer Therapies Annual Sales by Company (2021-2026)
3.1.2 Global Targeting p53 Cancer Therapies Sales Market Share by Company (2021-2026)
3.2 Global Targeting p53 Cancer Therapies Annual Revenue by Company (2021-2026)
3.2.1 Global Targeting p53 Cancer Therapies Revenue by Company (2021-2026)
3.2.2 Global Targeting p53 Cancer Therapies Revenue Market Share by Company (2021-2026)
3.3 Global Targeting p53 Cancer Therapies Sale Price by Company
3.4 Key Manufacturers Targeting p53 Cancer Therapies Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Targeting p53 Cancer Therapies Product Location Distribution
3.4.2 Players Targeting p53 Cancer Therapies Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR TARGETING P53 CANCER THERAPIES BY GEOGRAPHIC REGION
4.1 World Historic Targeting p53 Cancer Therapies Market Size by Geographic Region (2021-2026)
4.1.1 Global Targeting p53 Cancer Therapies Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Targeting p53 Cancer Therapies Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Targeting p53 Cancer Therapies Market Size by Country/Region (2021-2026)
4.2.1 Global Targeting p53 Cancer Therapies Annual Sales by Country/Region (2021-2026)
4.2.2 Global Targeting p53 Cancer Therapies Annual Revenue by Country/Region (2021-2026)
4.3 Americas Targeting p53 Cancer Therapies Sales Growth
4.4 APAC Targeting p53 Cancer Therapies Sales Growth
4.5 Europe Targeting p53 Cancer Therapies Sales Growth
4.6 Middle East & Africa Targeting p53 Cancer Therapies Sales Growth
5 AMERICAS
5.1 Americas Targeting p53 Cancer Therapies Sales by Country
5.1.1 Americas Targeting p53 Cancer Therapies Sales by Country (2021-2026)
5.1.2 Americas Targeting p53 Cancer Therapies Revenue by Country (2021-2026)
5.2 Americas Targeting p53 Cancer Therapies Sales by Type (2021-2026)
5.3 Americas Targeting p53 Cancer Therapies Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Targeting p53 Cancer Therapies Sales by Region
6.1.1 APAC Targeting p53 Cancer Therapies Sales by Region (2021-2026)
6.1.2 APAC Targeting p53 Cancer Therapies Revenue by Region (2021-2026)
6.2 APAC Targeting p53 Cancer Therapies Sales by Type (2021-2026)
6.3 APAC Targeting p53 Cancer Therapies Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Targeting p53 Cancer Therapies by Country
7.1.1 Europe Targeting p53 Cancer Therapies Sales by Country (2021-2026)
7.1.2 Europe Targeting p53 Cancer Therapies Revenue by Country (2021-2026)
7.2 Europe Targeting p53 Cancer Therapies Sales by Type (2021-2026)
7.3 Europe Targeting p53 Cancer Therapies Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Targeting p53 Cancer Therapies by Country
8.1.1 Middle East & Africa Targeting p53 Cancer Therapies Sales by Country (2021-2026)
8.1.2 Middle East & Africa Targeting p53 Cancer Therapies Revenue by Country (2021-2026)
8.2 Middle East & Africa Targeting p53 Cancer Therapies Sales by Type (2021-2026)
8.3 Middle East & Africa Targeting p53 Cancer Therapies Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Targeting p53 Cancer Therapies
10.3 Manufacturing Process Analysis of Targeting p53 Cancer Therapies
10.4 Industry Chain Structure of Targeting p53 Cancer Therapies
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Targeting p53 Cancer Therapies Distributors
11.3 Targeting p53 Cancer Therapies Customer
12 WORLD FORECAST REVIEW FOR TARGETING P53 CANCER THERAPIES BY GEOGRAPHIC REGION
12.1 Global Targeting p53 Cancer Therapies Market Size Forecast by Region
12.1.1 Global Targeting p53 Cancer Therapies Forecast by Region (2027-2032)
12.1.2 Global Targeting p53 Cancer Therapies Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Targeting p53 Cancer Therapies Forecast by Type (2027-2032)
12.7 Global Targeting p53 Cancer Therapies Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Sibiono GeneTech
13.1.1 Sibiono GeneTech Company Information
13.1.2 Sibiono GeneTech Targeting p53 Cancer Therapies Product Portfolios and Specifications
13.1.3 Sibiono GeneTech Targeting p53 Cancer Therapies Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Sibiono GeneTech Main Business Overview
13.1.5 Sibiono GeneTech Latest Developments
13.2 Kartos Therapeutics
13.2.1 Kartos Therapeutics Company Information
13.2.2 Kartos Therapeutics Targeting p53 Cancer Therapies Product Portfolios and Specifications
13.2.3 Kartos Therapeutics Targeting p53 Cancer Therapies Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Kartos Therapeutics Main Business Overview
13.2.5 Kartos Therapeutics Latest Developments
13.3 SynerGene Therapeutics
13.3.1 SynerGene Therapeutics Company Information
13.3.2 SynerGene Therapeutics Targeting p53 Cancer Therapies Product Portfolios and Specifications
13.3.3 SynerGene Therapeutics Targeting p53 Cancer Therapies Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 SynerGene Therapeutics Main Business Overview
13.3.5 SynerGene Therapeutics Latest Developments
13.4 MultiVir
13.4.1 MultiVir Company Information
13.4.2 MultiVir Targeting p53 Cancer Therapies Product Portfolios and Specifications
13.4.3 MultiVir Targeting p53 Cancer Therapies Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 MultiVir Main Business Overview
13.4.5 MultiVir Latest Developments
13.5 Rain Oncology
13.5.1 Rain Oncology Company Information
13.5.2 Rain Oncology Targeting p53 Cancer Therapies Product Portfolios and Specifications
13.5.3 Rain Oncology Targeting p53 Cancer Therapies Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Rain Oncology Main Business Overview
13.5.5 Rain Oncology Latest Developments
13.6 Alieron Therapeutics
13.6.1 Alieron Therapeutics Company Information
13.6.2 Alieron Therapeutics Targeting p53 Cancer Therapies Product Portfolios and Specifications
13.6.3 Alieron Therapeutics Targeting p53 Cancer Therapies Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Alieron Therapeutics Main Business Overview
13.6.5 Alieron Therapeutics Latest Developments
13.7 Aprea Therapeutics
13.7.1 Aprea Therapeutics Company Information
13.7.2 Aprea Therapeutics Targeting p53 Cancer Therapies Product Portfolios and Specifications
13.7.3 Aprea Therapeutics Targeting p53 Cancer Therapies Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Aprea Therapeutics Main Business Overview
13.7.5 Aprea Therapeutics Latest Developments
13.8 Ascentage Pharma
13.8.1 Ascentage Pharma Company Information
13.8.2 Ascentage Pharma Targeting p53 Cancer Therapies Product Portfolios and Specifications
13.8.3 Ascentage Pharma Targeting p53 Cancer Therapies Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Ascentage Pharma Main Business Overview
13.8.5 Ascentage Pharma Latest Developments
13.9 Jc (Wuxi) Company
13.9.1 Jc (Wuxi) Company Company Information
13.9.2 Jc (Wuxi) Company Targeting p53 Cancer Therapies Product Portfolios and Specifications
13.9.3 Jc (Wuxi) Company Targeting p53 Cancer Therapies Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Jc (Wuxi) Company Main Business Overview
13.9.5 Jc (Wuxi) Company Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Targeting p53 Cancer Therapies Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Targeting p53 Cancer Therapies Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Small Molecule Drugs
Table 4. Major Players of Immunotherapy
Table 5. Major Players of Gene Therapy
Table 6. Major Players of Others
Table 7. Global Targeting p53 Cancer Therapies Sales by Type (2021-2026) & (K Units)
Table 8. Global Targeting p53 Cancer Therapies Sales Market Share by Type (2021-2026)
Table 9. Global Targeting p53 Cancer Therapies Revenue by Type (2021-2026) & ($ million)
Table 10. Global Targeting p53 Cancer Therapies Revenue Market Share by Type (2021-2026)
Table 11. Global Targeting p53 Cancer Therapies Sale Price by Type (2021-2026) & (US$/Unit)
Table 12. Global Targeting p53 Cancer Therapies Sale by Application (2021-2026) & (K Units)
Table 13. Global Targeting p53 Cancer Therapies Sale Market Share by Application (2021-2026)
Table 14. Global Targeting p53 Cancer Therapies Revenue by Application (2021-2026) & ($ million)
Table 15. Global Targeting p53 Cancer Therapies Revenue Market Share by Application (2021-2026)
Table 16. Global Targeting p53 Cancer Therapies Sale Price by Application (2021-2026) & (US$/Unit)
Table 17. Global Targeting p53 Cancer Therapies Sales by Company (2021-2026) & (K Units)
Table 18. Global Targeting p53 Cancer Therapies Sales Market Share by Company (2021-2026)
Table 19. Global Targeting p53 Cancer Therapies Revenue by Company (2021-2026) & ($ millions)
Table 20. Global Targeting p53 Cancer Therapies Revenue Market Share by Company (2021-2026)
Table 21. Global Targeting p53 Cancer Therapies Sale Price by Company (2021-2026) & (US$/Unit)
Table 22. Key Manufacturers Targeting p53 Cancer Therapies Producing Area Distribution and Sales Area
Table 23. Players Targeting p53 Cancer Therapies Products Offered
Table 24. Targeting p53 Cancer Therapies Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 25. New Products and Potential Entrants
Table 26. Market M&A Activity & Strategy
Table 27. Global Targeting p53 Cancer Therapies Sales by Geographic Region (2021-2026) & (K Units)
Table 28. Global Targeting p53 Cancer Therapies Sales Market Share Geographic Region (2021-2026)
Table 29. Global Targeting p53 Cancer Therapies Revenue by Geographic Region (2021-2026) & ($ millions)
Table 30. Global Targeting p53 Cancer Therapies Revenue Market Share by Geographic Region (2021-2026)
Table 31. Global Targeting p53 Cancer Therapies Sales by Country/Region (2021-2026) & (K Units)
Table 32. Global Targeting p53 Cancer Therapies Sales Market Share by Country/Region (2021-2026)
Table 33. Global Targeting p53 Cancer Therapies Revenue by Country/Region (2021-2026) & ($ millions)
Table 34. Global Targeting p53 Cancer Therapies Revenue Market Share by Country/Region (2021-2026)
Table 35. Americas Targeting p53 Cancer Therapies Sales by Country (2021-2026) & (K Units)
Table 36. Americas Targeting p53 Cancer Therapies Sales Market Share by Country (2021-2026)
Table 37. Americas Targeting p53 Cancer Therapies Revenue by Country (2021-2026) & ($ millions)
Table 38. Americas Targeting p53 Cancer Therapies Sales by Type (2021-2026) & (K Units)
Table 39. Americas Targeting p53 Cancer Therapies Sales by Application (2021-2026) & (K Units)
Table 40. APAC Targeting p53 Cancer Therapies Sales by Region (2021-2026) & (K Units)
Table 41. APAC Targeting p53 Cancer Therapies Sales Market Share by Region (2021-2026)
Table 42. APAC Targeting p53 Cancer Therapies Revenue by Region (2021-2026) & ($ millions)
Table 43. APAC Targeting p53 Cancer Therapies Sales by Type (2021-2026) & (K Units)
Table 44. APAC Targeting p53 Cancer Therapies Sales by Application (2021-2026) & (K Units)
Table 45. Europe Targeting p53 Cancer Therapies Sales by Country (2021-2026) & (K Units)
Table 46. Europe Targeting p53 Cancer Therapies Revenue by Country (2021-2026) & ($ millions)
Table 47. Europe Targeting p53 Cancer Therapies Sales by Type (2021-2026) & (K Units)
Table 48. Europe Targeting p53 Cancer Therapies Sales by Application (2021-2026) & (K Units)
Table 49. Middle East & Africa Targeting p53 Cancer Therapies Sales by Country (2021-2026) & (K Units)
Table 50. Middle East & Africa Targeting p53 Cancer Therapies Revenue Market Share by Country (2021-2026)
Table 51. Middle East & Africa Targeting p53 Cancer Therapies Sales by Type (2021-2026) & (K Units)
Table 52. Middle East & Africa Targeting p53 Cancer Therapies Sales by Application (2021-2026) & (K Units)
Table 53. Key Market Drivers & Growth Opportunities of Targeting p53 Cancer Therapies
Table 54. Key Market Challenges & Risks of Targeting p53 Cancer Therapies
Table 55. Key Industry Trends of Targeting p53 Cancer Therapies
Table 56. Targeting p53 Cancer Therapies Raw Material
Table 57. Key Suppliers of Raw Materials
Table 58. Targeting p53 Cancer Therapies Distributors List
Table 59. Targeting p53 Cancer Therapies Customer List
Table 60. Global Targeting p53 Cancer Therapies Sales Forecast by Region (2027-2032) & (K Units)
Table 61. Global Targeting p53 Cancer Therapies Revenue Forecast by Region (2027-2032) & ($ millions)
Table 62. Americas Targeting p53 Cancer Therapies Sales Forecast by Country (2027-2032) & (K Units)
Table 63. Americas Targeting p53 Cancer Therapies Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 64. APAC Targeting p53 Cancer Therapies Sales Forecast by Region (2027-2032) & (K Units)
Table 65. APAC Targeting p53 Cancer Therapies Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 66. Europe Targeting p53 Cancer Therapies Sales Forecast by Country (2027-2032) & (K Units)
Table 67. Europe Targeting p53 Cancer Therapies Revenue Forecast by Country (2027-2032) & ($ millions)
Table 68. Middle East & Africa Targeting p53 Cancer Therapies Sales Forecast by Country (2027-2032) & (K Units)
Table 69. Middle East & Africa Targeting p53 Cancer Therapies Revenue Forecast by Country (2027-2032) & ($ millions)
Table 70. Global Targeting p53 Cancer Therapies Sales Forecast by Type (2027-2032) & (K Units)
Table 71. Global Targeting p53 Cancer Therapies Revenue Forecast by Type (2027-2032) & ($ millions)
Table 72. Global Targeting p53 Cancer Therapies Sales Forecast by Application (2027-2032) & (K Units)
Table 73. Global Targeting p53 Cancer Therapies Revenue Forecast by Application (2027-2032) & ($ millions)
Table 74. Sibiono GeneTech Basic Information, Targeting p53 Cancer Therapies Manufacturing Base, Sales Area and Its Competitors
Table 75. Sibiono GeneTech Targeting p53 Cancer Therapies Product Portfolios and Specifications
Table 76. Sibiono GeneTech Targeting p53 Cancer Therapies Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 77. Sibiono GeneTech Main Business
Table 78. Sibiono GeneTech Latest Developments
Table 79. Kartos Therapeutics Basic Information, Targeting p53 Cancer Therapies Manufacturing Base, Sales Area and Its Competitors
Table 80. Kartos Therapeutics Targeting p53 Cancer Therapies Product Portfolios and Specifications
Table 81. Kartos Therapeutics Targeting p53 Cancer Therapies Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 82. Kartos Therapeutics Main Business
Table 83. Kartos Therapeutics Latest Developments
Table 84. SynerGene Therapeutics Basic Information, Targeting p53 Cancer Therapies Manufacturing Base, Sales Area and Its Competitors
Table 85. SynerGene Therapeutics Targeting p53 Cancer Therapies Product Portfolios and Specifications
Table 86. SynerGene Therapeutics Targeting p53 Cancer Therapies Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 87. SynerGene Therapeutics Main Business
Table 88. SynerGene Therapeutics Latest Developments
Table 89. MultiVir Basic Information, Targeting p53 Cancer Therapies Manufacturing Base, Sales Area and Its Competitors
Table 90. MultiVir Targeting p53 Cancer Therapies Product Portfolios and Specifications
Table 91. MultiVir Targeting p53 Cancer Therapies Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 92. MultiVir Main Business
Table 93. MultiVir Latest Developments
Table 94. Rain Oncology Basic Information, Targeting p53 Cancer Therapies Manufacturing Base, Sales Area and Its Competitors
Table 95. Rain Oncology Targeting p53 Cancer Therapies Product Portfolios and Specifications
Table 96. Rain Oncology Targeting p53 Cancer Therapies Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 97. Rain Oncology Main Business
Table 98. Rain Oncology Latest Developments
Table 99. Alieron Therapeutics Basic Information, Targeting p53 Cancer Therapies Manufacturing Base, Sales Area and Its Competitors
Table 100. Alieron Therapeutics Targeting p53 Cancer Therapies Product Portfolios and Specifications
Table 101. Alieron Therapeutics Targeting p53 Cancer Therapies Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 102. Alieron Therapeutics Main Business
Table 103. Alieron Therapeutics Latest Developments
Table 104. Aprea Therapeutics Basic Information, Targeting p53 Cancer Therapies Manufacturing Base, Sales Area and Its Competitors
Table 105. Aprea Therapeutics Targeting p53 Cancer Therapies Product Portfolios and Specifications
Table 106. Aprea Therapeutics Targeting p53 Cancer Therapies Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 107. Aprea Therapeutics Main Business
Table 108. Aprea Therapeutics Latest Developments
Table 109. Ascentage Pharma Basic Information, Targeting p53 Cancer Therapies Manufacturing Base, Sales Area and Its Competitors
Table 110. Ascentage Pharma Targeting p53 Cancer Therapies Product Portfolios and Specifications
Table 111. Ascentage Pharma Targeting p53 Cancer Therapies Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 112. Ascentage Pharma Main Business
Table 113. Ascentage Pharma Latest Developments
Table 114. Jc (Wuxi) Company Basic Information, Targeting p53 Cancer Therapies Manufacturing Base, Sales Area and Its Competitors
Table 115. Jc (Wuxi) Company Targeting p53 Cancer Therapies Product Portfolios and Specifications
Table 116. Jc (Wuxi) Company Targeting p53 Cancer Therapies Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 117. Jc (Wuxi) Company Main Business
Table 118. Jc (Wuxi) Company Latest Developments
Table 1. Targeting p53 Cancer Therapies Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Targeting p53 Cancer Therapies Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Small Molecule Drugs
Table 4. Major Players of Immunotherapy
Table 5. Major Players of Gene Therapy
Table 6. Major Players of Others
Table 7. Global Targeting p53 Cancer Therapies Sales by Type (2021-2026) & (K Units)
Table 8. Global Targeting p53 Cancer Therapies Sales Market Share by Type (2021-2026)
Table 9. Global Targeting p53 Cancer Therapies Revenue by Type (2021-2026) & ($ million)
Table 10. Global Targeting p53 Cancer Therapies Revenue Market Share by Type (2021-2026)
Table 11. Global Targeting p53 Cancer Therapies Sale Price by Type (2021-2026) & (US$/Unit)
Table 12. Global Targeting p53 Cancer Therapies Sale by Application (2021-2026) & (K Units)
Table 13. Global Targeting p53 Cancer Therapies Sale Market Share by Application (2021-2026)
Table 14. Global Targeting p53 Cancer Therapies Revenue by Application (2021-2026) & ($ million)
Table 15. Global Targeting p53 Cancer Therapies Revenue Market Share by Application (2021-2026)
Table 16. Global Targeting p53 Cancer Therapies Sale Price by Application (2021-2026) & (US$/Unit)
Table 17. Global Targeting p53 Cancer Therapies Sales by Company (2021-2026) & (K Units)
Table 18. Global Targeting p53 Cancer Therapies Sales Market Share by Company (2021-2026)
Table 19. Global Targeting p53 Cancer Therapies Revenue by Company (2021-2026) & ($ millions)
Table 20. Global Targeting p53 Cancer Therapies Revenue Market Share by Company (2021-2026)
Table 21. Global Targeting p53 Cancer Therapies Sale Price by Company (2021-2026) & (US$/Unit)
Table 22. Key Manufacturers Targeting p53 Cancer Therapies Producing Area Distribution and Sales Area
Table 23. Players Targeting p53 Cancer Therapies Products Offered
Table 24. Targeting p53 Cancer Therapies Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 25. New Products and Potential Entrants
Table 26. Market M&A Activity & Strategy
Table 27. Global Targeting p53 Cancer Therapies Sales by Geographic Region (2021-2026) & (K Units)
Table 28. Global Targeting p53 Cancer Therapies Sales Market Share Geographic Region (2021-2026)
Table 29. Global Targeting p53 Cancer Therapies Revenue by Geographic Region (2021-2026) & ($ millions)
Table 30. Global Targeting p53 Cancer Therapies Revenue Market Share by Geographic Region (2021-2026)
Table 31. Global Targeting p53 Cancer Therapies Sales by Country/Region (2021-2026) & (K Units)
Table 32. Global Targeting p53 Cancer Therapies Sales Market Share by Country/Region (2021-2026)
Table 33. Global Targeting p53 Cancer Therapies Revenue by Country/Region (2021-2026) & ($ millions)
Table 34. Global Targeting p53 Cancer Therapies Revenue Market Share by Country/Region (2021-2026)
Table 35. Americas Targeting p53 Cancer Therapies Sales by Country (2021-2026) & (K Units)
Table 36. Americas Targeting p53 Cancer Therapies Sales Market Share by Country (2021-2026)
Table 37. Americas Targeting p53 Cancer Therapies Revenue by Country (2021-2026) & ($ millions)
Table 38. Americas Targeting p53 Cancer Therapies Sales by Type (2021-2026) & (K Units)
Table 39. Americas Targeting p53 Cancer Therapies Sales by Application (2021-2026) & (K Units)
Table 40. APAC Targeting p53 Cancer Therapies Sales by Region (2021-2026) & (K Units)
Table 41. APAC Targeting p53 Cancer Therapies Sales Market Share by Region (2021-2026)
Table 42. APAC Targeting p53 Cancer Therapies Revenue by Region (2021-2026) & ($ millions)
Table 43. APAC Targeting p53 Cancer Therapies Sales by Type (2021-2026) & (K Units)
Table 44. APAC Targeting p53 Cancer Therapies Sales by Application (2021-2026) & (K Units)
Table 45. Europe Targeting p53 Cancer Therapies Sales by Country (2021-2026) & (K Units)
Table 46. Europe Targeting p53 Cancer Therapies Revenue by Country (2021-2026) & ($ millions)
Table 47. Europe Targeting p53 Cancer Therapies Sales by Type (2021-2026) & (K Units)
Table 48. Europe Targeting p53 Cancer Therapies Sales by Application (2021-2026) & (K Units)
Table 49. Middle East & Africa Targeting p53 Cancer Therapies Sales by Country (2021-2026) & (K Units)
Table 50. Middle East & Africa Targeting p53 Cancer Therapies Revenue Market Share by Country (2021-2026)
Table 51. Middle East & Africa Targeting p53 Cancer Therapies Sales by Type (2021-2026) & (K Units)
Table 52. Middle East & Africa Targeting p53 Cancer Therapies Sales by Application (2021-2026) & (K Units)
Table 53. Key Market Drivers & Growth Opportunities of Targeting p53 Cancer Therapies
Table 54. Key Market Challenges & Risks of Targeting p53 Cancer Therapies
Table 55. Key Industry Trends of Targeting p53 Cancer Therapies
Table 56. Targeting p53 Cancer Therapies Raw Material
Table 57. Key Suppliers of Raw Materials
Table 58. Targeting p53 Cancer Therapies Distributors List
Table 59. Targeting p53 Cancer Therapies Customer List
Table 60. Global Targeting p53 Cancer Therapies Sales Forecast by Region (2027-2032) & (K Units)
Table 61. Global Targeting p53 Cancer Therapies Revenue Forecast by Region (2027-2032) & ($ millions)
Table 62. Americas Targeting p53 Cancer Therapies Sales Forecast by Country (2027-2032) & (K Units)
Table 63. Americas Targeting p53 Cancer Therapies Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 64. APAC Targeting p53 Cancer Therapies Sales Forecast by Region (2027-2032) & (K Units)
Table 65. APAC Targeting p53 Cancer Therapies Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 66. Europe Targeting p53 Cancer Therapies Sales Forecast by Country (2027-2032) & (K Units)
Table 67. Europe Targeting p53 Cancer Therapies Revenue Forecast by Country (2027-2032) & ($ millions)
Table 68. Middle East & Africa Targeting p53 Cancer Therapies Sales Forecast by Country (2027-2032) & (K Units)
Table 69. Middle East & Africa Targeting p53 Cancer Therapies Revenue Forecast by Country (2027-2032) & ($ millions)
Table 70. Global Targeting p53 Cancer Therapies Sales Forecast by Type (2027-2032) & (K Units)
Table 71. Global Targeting p53 Cancer Therapies Revenue Forecast by Type (2027-2032) & ($ millions)
Table 72. Global Targeting p53 Cancer Therapies Sales Forecast by Application (2027-2032) & (K Units)
Table 73. Global Targeting p53 Cancer Therapies Revenue Forecast by Application (2027-2032) & ($ millions)
Table 74. Sibiono GeneTech Basic Information, Targeting p53 Cancer Therapies Manufacturing Base, Sales Area and Its Competitors
Table 75. Sibiono GeneTech Targeting p53 Cancer Therapies Product Portfolios and Specifications
Table 76. Sibiono GeneTech Targeting p53 Cancer Therapies Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 77. Sibiono GeneTech Main Business
Table 78. Sibiono GeneTech Latest Developments
Table 79. Kartos Therapeutics Basic Information, Targeting p53 Cancer Therapies Manufacturing Base, Sales Area and Its Competitors
Table 80. Kartos Therapeutics Targeting p53 Cancer Therapies Product Portfolios and Specifications
Table 81. Kartos Therapeutics Targeting p53 Cancer Therapies Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 82. Kartos Therapeutics Main Business
Table 83. Kartos Therapeutics Latest Developments
Table 84. SynerGene Therapeutics Basic Information, Targeting p53 Cancer Therapies Manufacturing Base, Sales Area and Its Competitors
Table 85. SynerGene Therapeutics Targeting p53 Cancer Therapies Product Portfolios and Specifications
Table 86. SynerGene Therapeutics Targeting p53 Cancer Therapies Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 87. SynerGene Therapeutics Main Business
Table 88. SynerGene Therapeutics Latest Developments
Table 89. MultiVir Basic Information, Targeting p53 Cancer Therapies Manufacturing Base, Sales Area and Its Competitors
Table 90. MultiVir Targeting p53 Cancer Therapies Product Portfolios and Specifications
Table 91. MultiVir Targeting p53 Cancer Therapies Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 92. MultiVir Main Business
Table 93. MultiVir Latest Developments
Table 94. Rain Oncology Basic Information, Targeting p53 Cancer Therapies Manufacturing Base, Sales Area and Its Competitors
Table 95. Rain Oncology Targeting p53 Cancer Therapies Product Portfolios and Specifications
Table 96. Rain Oncology Targeting p53 Cancer Therapies Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 97. Rain Oncology Main Business
Table 98. Rain Oncology Latest Developments
Table 99. Alieron Therapeutics Basic Information, Targeting p53 Cancer Therapies Manufacturing Base, Sales Area and Its Competitors
Table 100. Alieron Therapeutics Targeting p53 Cancer Therapies Product Portfolios and Specifications
Table 101. Alieron Therapeutics Targeting p53 Cancer Therapies Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 102. Alieron Therapeutics Main Business
Table 103. Alieron Therapeutics Latest Developments
Table 104. Aprea Therapeutics Basic Information, Targeting p53 Cancer Therapies Manufacturing Base, Sales Area and Its Competitors
Table 105. Aprea Therapeutics Targeting p53 Cancer Therapies Product Portfolios and Specifications
Table 106. Aprea Therapeutics Targeting p53 Cancer Therapies Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 107. Aprea Therapeutics Main Business
Table 108. Aprea Therapeutics Latest Developments
Table 109. Ascentage Pharma Basic Information, Targeting p53 Cancer Therapies Manufacturing Base, Sales Area and Its Competitors
Table 110. Ascentage Pharma Targeting p53 Cancer Therapies Product Portfolios and Specifications
Table 111. Ascentage Pharma Targeting p53 Cancer Therapies Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 112. Ascentage Pharma Main Business
Table 113. Ascentage Pharma Latest Developments
Table 114. Jc (Wuxi) Company Basic Information, Targeting p53 Cancer Therapies Manufacturing Base, Sales Area and Its Competitors
Table 115. Jc (Wuxi) Company Targeting p53 Cancer Therapies Product Portfolios and Specifications
Table 116. Jc (Wuxi) Company Targeting p53 Cancer Therapies Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 117. Jc (Wuxi) Company Main Business
Table 118. Jc (Wuxi) Company Latest Developments
LIST OF FIGURES
Figure 1. Picture of Targeting p53 Cancer Therapies
Figure 2. Targeting p53 Cancer Therapies Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Targeting p53 Cancer Therapies Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Targeting p53 Cancer Therapies Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Targeting p53 Cancer Therapies Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Targeting p53 Cancer Therapies Sales Market Share by Country/Region (2025)
Figure 10. Targeting p53 Cancer Therapies Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Small Molecule Drugs
Figure 12. Product Picture of Immunotherapy
Figure 13. Product Picture of Gene Therapy
Figure 14. Product Picture of Others
Figure 15. Global Targeting p53 Cancer Therapies Sales Market Share by Type in 2026
Figure 16. Global Targeting p53 Cancer Therapies Revenue Market Share by Type (2021-2026)
Figure 17. Targeting p53 Cancer Therapies Consumed in Hospital
Figure 18. Global Targeting p53 Cancer Therapies Market: Hospital (2021-2026) & (K Units)
Figure 19. Targeting p53 Cancer Therapies Consumed in Clinic
Figure 20. Global Targeting p53 Cancer Therapies Market: Clinic (2021-2026) & (K Units)
Figure 21. Targeting p53 Cancer Therapies Consumed in Others
Figure 22. Global Targeting p53 Cancer Therapies Market: Others (2021-2026) & (K Units)
Figure 23. Global Targeting p53 Cancer Therapies Sale Market Share by Application (2025)
Figure 24. Global Targeting p53 Cancer Therapies Revenue Market Share by Application in 2026
Figure 25. Targeting p53 Cancer Therapies Sales by Company in 2026 (K Units)
Figure 26. Global Targeting p53 Cancer Therapies Sales Market Share by Company in 2026
Figure 27. Targeting p53 Cancer Therapies Revenue by Company in 2026 ($ millions)
Figure 28. Global Targeting p53 Cancer Therapies Revenue Market Share by Company in 2026
Figure 29. Global Targeting p53 Cancer Therapies Sales Market Share by Geographic Region (2021-2026)
Figure 30. Global Targeting p53 Cancer Therapies Revenue Market Share by Geographic Region in 2026
Figure 31. Americas Targeting p53 Cancer Therapies Sales 2021-2026 (K Units)
Figure 32. Americas Targeting p53 Cancer Therapies Revenue 2021-2026 ($ millions)
Figure 33. APAC Targeting p53 Cancer Therapies Sales 2021-2026 (K Units)
Figure 34. APAC Targeting p53 Cancer Therapies Revenue 2021-2026 ($ millions)
Figure 35. Europe Targeting p53 Cancer Therapies Sales 2021-2026 (K Units)
Figure 36. Europe Targeting p53 Cancer Therapies Revenue 2021-2026 ($ millions)
Figure 37. Middle East & Africa Targeting p53 Cancer Therapies Sales 2021-2026 (K Units)
Figure 38. Middle East & Africa Targeting p53 Cancer Therapies Revenue 2021-2026 ($ millions)
Figure 39. Americas Targeting p53 Cancer Therapies Sales Market Share by Country in 2026
Figure 40. Americas Targeting p53 Cancer Therapies Revenue Market Share by Country (2021-2026)
Figure 41. Americas Targeting p53 Cancer Therapies Sales Market Share by Type (2021-2026)
Figure 42. Americas Targeting p53 Cancer Therapies Sales Market Share by Application (2021-2026)
Figure 43. United States Targeting p53 Cancer Therapies Revenue Growth 2021-2026 ($ millions)
Figure 44. Canada Targeting p53 Cancer Therapies Revenue Growth 2021-2026 ($ millions)
Figure 45. Mexico Targeting p53 Cancer Therapies Revenue Growth 2021-2026 ($ millions)
Figure 46. Brazil Targeting p53 Cancer Therapies Revenue Growth 2021-2026 ($ millions)
Figure 47. APAC Targeting p53 Cancer Therapies Sales Market Share by Region in 2026
Figure 48. APAC Targeting p53 Cancer Therapies Revenue Market Share by Region (2021-2026)
Figure 49. APAC Targeting p53 Cancer Therapies Sales Market Share by Type (2021-2026)
Figure 50. APAC Targeting p53 Cancer Therapies Sales Market Share by Application (2021-2026)
Figure 51. China Targeting p53 Cancer Therapies Revenue Growth 2021-2026 ($ millions)
Figure 52. Japan Targeting p53 Cancer Therapies Revenue Growth 2021-2026 ($ millions)
Figure 53. South Korea Targeting p53 Cancer Therapies Revenue Growth 2021-2026 ($ millions)
Figure 54. Southeast Asia Targeting p53 Cancer Therapies Revenue Growth 2021-2026 ($ millions)
Figure 55. India Targeting p53 Cancer Therapies Revenue Growth 2021-2026 ($ millions)
Figure 56. Australia Targeting p53 Cancer Therapies Revenue Growth 2021-2026 ($ millions)
Figure 57. China Taiwan Targeting p53 Cancer Therapies Revenue Growth 2021-2026 ($ millions)
Figure 58. Europe Targeting p53 Cancer Therapies Sales Market Share by Country in 2026
Figure 59. Europe Targeting p53 Cancer Therapies Revenue Market Share by Country (2021-2026)
Figure 60. Europe Targeting p53 Cancer Therapies Sales Market Share by Type (2021-2026)
Figure 61. Europe Targeting p53 Cancer Therapies Sales Market Share by Application (2021-2026)
Figure 62. Germany Targeting p53 Cancer Therapies Revenue Growth 2021-2026 ($ millions)
Figure 63. France Targeting p53 Cancer Therapies Revenue Growth 2021-2026 ($ millions)
Figure 64. UK Targeting p53 Cancer Therapies Revenue Growth 2021-2026 ($ millions)
Figure 65. Italy Targeting p53 Cancer Therapies Revenue Growth 2021-2026 ($ millions)
Figure 66. Russia Targeting p53 Cancer Therapies Revenue Growth 2021-2026 ($ millions)
Figure 67. Middle East & Africa Targeting p53 Cancer Therapies Sales Market Share by Country (2021-2026)
Figure 68. Middle East & Africa Targeting p53 Cancer Therapies Sales Market Share by Type (2021-2026)
Figure 69. Middle East & Africa Targeting p53 Cancer Therapies Sales Market Share by Application (2021-2026)
Figure 70. Egypt Targeting p53 Cancer Therapies Revenue Growth 2021-2026 ($ millions)
Figure 71. South Africa Targeting p53 Cancer Therapies Revenue Growth 2021-2026 ($ millions)
Figure 72. Israel Targeting p53 Cancer Therapies Revenue Growth 2021-2026 ($ millions)
Figure 73. Turkey Targeting p53 Cancer Therapies Revenue Growth 2021-2026 ($ millions)
Figure 74. GCC Countries Targeting p53 Cancer Therapies Revenue Growth 2021-2026 ($ millions)
Figure 75. Manufacturing Cost Structure Analysis of Targeting p53 Cancer Therapies in 2026
Figure 76. Manufacturing Process Analysis of Targeting p53 Cancer Therapies
Figure 77. Industry Chain Structure of Targeting p53 Cancer Therapies
Figure 78. Channels of Distribution
Figure 79. Global Targeting p53 Cancer Therapies Sales Market Forecast by Region (2027-2032)
Figure 80. Global Targeting p53 Cancer Therapies Revenue Market Share Forecast by Region (2027-2032)
Figure 81. Global Targeting p53 Cancer Therapies Sales Market Share Forecast by Type (2027-2032)
Figure 82. Global Targeting p53 Cancer Therapies Revenue Market Share Forecast by Type (2027-2032)
Figure 83. Global Targeting p53 Cancer Therapies Sales Market Share Forecast by Application (2027-2032)
Figure 84. Global Targeting p53 Cancer Therapies Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of Targeting p53 Cancer Therapies
Figure 2. Targeting p53 Cancer Therapies Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Targeting p53 Cancer Therapies Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Targeting p53 Cancer Therapies Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Targeting p53 Cancer Therapies Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Targeting p53 Cancer Therapies Sales Market Share by Country/Region (2025)
Figure 10. Targeting p53 Cancer Therapies Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Small Molecule Drugs
Figure 12. Product Picture of Immunotherapy
Figure 13. Product Picture of Gene Therapy
Figure 14. Product Picture of Others
Figure 15. Global Targeting p53 Cancer Therapies Sales Market Share by Type in 2026
Figure 16. Global Targeting p53 Cancer Therapies Revenue Market Share by Type (2021-2026)
Figure 17. Targeting p53 Cancer Therapies Consumed in Hospital
Figure 18. Global Targeting p53 Cancer Therapies Market: Hospital (2021-2026) & (K Units)
Figure 19. Targeting p53 Cancer Therapies Consumed in Clinic
Figure 20. Global Targeting p53 Cancer Therapies Market: Clinic (2021-2026) & (K Units)
Figure 21. Targeting p53 Cancer Therapies Consumed in Others
Figure 22. Global Targeting p53 Cancer Therapies Market: Others (2021-2026) & (K Units)
Figure 23. Global Targeting p53 Cancer Therapies Sale Market Share by Application (2025)
Figure 24. Global Targeting p53 Cancer Therapies Revenue Market Share by Application in 2026
Figure 25. Targeting p53 Cancer Therapies Sales by Company in 2026 (K Units)
Figure 26. Global Targeting p53 Cancer Therapies Sales Market Share by Company in 2026
Figure 27. Targeting p53 Cancer Therapies Revenue by Company in 2026 ($ millions)
Figure 28. Global Targeting p53 Cancer Therapies Revenue Market Share by Company in 2026
Figure 29. Global Targeting p53 Cancer Therapies Sales Market Share by Geographic Region (2021-2026)
Figure 30. Global Targeting p53 Cancer Therapies Revenue Market Share by Geographic Region in 2026
Figure 31. Americas Targeting p53 Cancer Therapies Sales 2021-2026 (K Units)
Figure 32. Americas Targeting p53 Cancer Therapies Revenue 2021-2026 ($ millions)
Figure 33. APAC Targeting p53 Cancer Therapies Sales 2021-2026 (K Units)
Figure 34. APAC Targeting p53 Cancer Therapies Revenue 2021-2026 ($ millions)
Figure 35. Europe Targeting p53 Cancer Therapies Sales 2021-2026 (K Units)
Figure 36. Europe Targeting p53 Cancer Therapies Revenue 2021-2026 ($ millions)
Figure 37. Middle East & Africa Targeting p53 Cancer Therapies Sales 2021-2026 (K Units)
Figure 38. Middle East & Africa Targeting p53 Cancer Therapies Revenue 2021-2026 ($ millions)
Figure 39. Americas Targeting p53 Cancer Therapies Sales Market Share by Country in 2026
Figure 40. Americas Targeting p53 Cancer Therapies Revenue Market Share by Country (2021-2026)
Figure 41. Americas Targeting p53 Cancer Therapies Sales Market Share by Type (2021-2026)
Figure 42. Americas Targeting p53 Cancer Therapies Sales Market Share by Application (2021-2026)
Figure 43. United States Targeting p53 Cancer Therapies Revenue Growth 2021-2026 ($ millions)
Figure 44. Canada Targeting p53 Cancer Therapies Revenue Growth 2021-2026 ($ millions)
Figure 45. Mexico Targeting p53 Cancer Therapies Revenue Growth 2021-2026 ($ millions)
Figure 46. Brazil Targeting p53 Cancer Therapies Revenue Growth 2021-2026 ($ millions)
Figure 47. APAC Targeting p53 Cancer Therapies Sales Market Share by Region in 2026
Figure 48. APAC Targeting p53 Cancer Therapies Revenue Market Share by Region (2021-2026)
Figure 49. APAC Targeting p53 Cancer Therapies Sales Market Share by Type (2021-2026)
Figure 50. APAC Targeting p53 Cancer Therapies Sales Market Share by Application (2021-2026)
Figure 51. China Targeting p53 Cancer Therapies Revenue Growth 2021-2026 ($ millions)
Figure 52. Japan Targeting p53 Cancer Therapies Revenue Growth 2021-2026 ($ millions)
Figure 53. South Korea Targeting p53 Cancer Therapies Revenue Growth 2021-2026 ($ millions)
Figure 54. Southeast Asia Targeting p53 Cancer Therapies Revenue Growth 2021-2026 ($ millions)
Figure 55. India Targeting p53 Cancer Therapies Revenue Growth 2021-2026 ($ millions)
Figure 56. Australia Targeting p53 Cancer Therapies Revenue Growth 2021-2026 ($ millions)
Figure 57. China Taiwan Targeting p53 Cancer Therapies Revenue Growth 2021-2026 ($ millions)
Figure 58. Europe Targeting p53 Cancer Therapies Sales Market Share by Country in 2026
Figure 59. Europe Targeting p53 Cancer Therapies Revenue Market Share by Country (2021-2026)
Figure 60. Europe Targeting p53 Cancer Therapies Sales Market Share by Type (2021-2026)
Figure 61. Europe Targeting p53 Cancer Therapies Sales Market Share by Application (2021-2026)
Figure 62. Germany Targeting p53 Cancer Therapies Revenue Growth 2021-2026 ($ millions)
Figure 63. France Targeting p53 Cancer Therapies Revenue Growth 2021-2026 ($ millions)
Figure 64. UK Targeting p53 Cancer Therapies Revenue Growth 2021-2026 ($ millions)
Figure 65. Italy Targeting p53 Cancer Therapies Revenue Growth 2021-2026 ($ millions)
Figure 66. Russia Targeting p53 Cancer Therapies Revenue Growth 2021-2026 ($ millions)
Figure 67. Middle East & Africa Targeting p53 Cancer Therapies Sales Market Share by Country (2021-2026)
Figure 68. Middle East & Africa Targeting p53 Cancer Therapies Sales Market Share by Type (2021-2026)
Figure 69. Middle East & Africa Targeting p53 Cancer Therapies Sales Market Share by Application (2021-2026)
Figure 70. Egypt Targeting p53 Cancer Therapies Revenue Growth 2021-2026 ($ millions)
Figure 71. South Africa Targeting p53 Cancer Therapies Revenue Growth 2021-2026 ($ millions)
Figure 72. Israel Targeting p53 Cancer Therapies Revenue Growth 2021-2026 ($ millions)
Figure 73. Turkey Targeting p53 Cancer Therapies Revenue Growth 2021-2026 ($ millions)
Figure 74. GCC Countries Targeting p53 Cancer Therapies Revenue Growth 2021-2026 ($ millions)
Figure 75. Manufacturing Cost Structure Analysis of Targeting p53 Cancer Therapies in 2026
Figure 76. Manufacturing Process Analysis of Targeting p53 Cancer Therapies
Figure 77. Industry Chain Structure of Targeting p53 Cancer Therapies
Figure 78. Channels of Distribution
Figure 79. Global Targeting p53 Cancer Therapies Sales Market Forecast by Region (2027-2032)
Figure 80. Global Targeting p53 Cancer Therapies Revenue Market Share Forecast by Region (2027-2032)
Figure 81. Global Targeting p53 Cancer Therapies Sales Market Share Forecast by Type (2027-2032)
Figure 82. Global Targeting p53 Cancer Therapies Revenue Market Share Forecast by Type (2027-2032)
Figure 83. Global Targeting p53 Cancer Therapies Sales Market Share Forecast by Application (2027-2032)
Figure 84. Global Targeting p53 Cancer Therapies Revenue Market Share Forecast by Application (2027-2032)
